Science
Mechanism of Action
Nitrosomonas eutropha operates by converting ammonia present in sweat into nitrite and nitric oxide (NO). Nitric oxide functions as a potent vasodilator, promoting increased blood circulation, and exhibits inherent antimicrobial and anti-inflammatory capabilities. It actively participates in regulating keratinocyte proliferation, with adequate levels supporting healthy skin cell turnover. Furthermore, it modulates immune responses by inhibiting Th2 immune polarization through the anti-inflammatory cytokine IL-10 and can mitigate the presence of problematic bacteria such as Propionibacterium acnes and Staphylococcus aureus via acidified nitrite production.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 A 7-day open-label trial on 29 individuals showed a slight, non-clinically significant improvement in skin radiance.
- 02 The same 7-day open-label trial on 29 individuals demonstrated improvements in wrinkle severity, wrinkle depth, and skin pigmentation, alongside a slight, non-clinically significant improvement in skin radiance.
- 03 A randomized clinical trial indicated potential to reduce the overall cutaneous inflammatory state and improve the cosmetic appearance of Keratosis Pilaris (KP).
Transparency
Dusting Analysis
Nitrosomonas eutropha is a living bacterial ingredient and is not associated with 'dusting' as a formulation concern.
The Formula
Formulation
Stability
Requires cold storage to maintain stability. It is inactivated by common liquid cleansers, particularly antibacterial soaps, and soaps formulated with vegetable oils or animal fats. Disodium phosphate and magnesium chloride are used as buffering agents for its optimal environment. Optimal growth occurs at pH 6, with ammonia oxidation ceasing around pH 5.4. Incorporating a gel-forming material can enhance nitric oxide penetration by reducing loss to ambient air.
Conflicts
- Common liquid cleansers
- Antibacterial soaps
- Soaps made with vegetable oils or animal fats
Safety
Safety Profile
The FDA currently lacks a regulatory definition for 'probiotic' and has not approved Nitrosomonas eutropha for therapeutic use. A company, AOBiome, has filed an Investigational New Drug (IND) application to test more concentrated forms for diabetic ulcers and other dermatologic conditions. Specific safety assessments for cosmetic use by CIR or SCCS are not readily available.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Nitrosomonas Eutropha presents as a valuable, unique skin-conditioning probiotic with a broad range of potential benefits, supported by a distinct mechanism and promising preliminary clinical data, though its specific formulation requirements and lack of comprehensive regulatory review necessitate careful consideration.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources